Antares Pharma (NASDAQ: ATRS) reported Q4 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $14.2 million versus the consensus estimate of $11.25 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.